Clinical trials recruiting for Major depressive disorder
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Ketamine | 10 |
| Ketamine Hydrochloride | 5 |
| NBI-1065845 | 5 |
| Psilocybin | 5 |
| Esketamine | 3 |
| Sertraline | 3 |
| Azetukalner | 2 |
| Bupropion | 2 |
| Escitalopram | 2 |
| Esketamine Nasal Product | 2 |
| Esketamine hydrochloride | 2 |
| Fluoxetine | 2 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| New York | 30 |
| California | 28 |
| Massachusetts | 24 |
| Texas | 22 |
| Florida | 18 |
| Ohio | 17 |
| Georgia | 15 |
| Pennsylvania | 14 |
| Connecticut | 11 |
| Illinois | 11 |
| Alabama | 10 |
| Oklahoma | 10 |
Top cities
Self-screener
Recruiting trials
- 40 Hz Light Neurostimulation for Patients With Depression (FELIX)
- 5-HTP and Creatine for Depression R33 Phase
- A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety
- A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD
- A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- A Randomized Neuroimaging Trial of Psilocybin in Depression
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
- A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Accelerated Intermittent Theta Burst in Treatment-Naive Adolescents
- Accelerated Intermittent Theta-Burst Stimulation Ameliorate Major Depressive Disorder by Regulating CAMKII Pathway
- Accelerated TMS for Perinatal Depression
- Accelerated Treatment of Depressive Patients With tDCS
- Accelerated Versus Standard Intermittent Theta Burst Stimulation for Major Depressive Disorder
- Adolescent Interpersonal Counseling in Primary Care
- Amygdala Neurofeedback for Depression - Large Scale Clinical Trial
- An Empirical Study on the Mechanisms of Biopsychosocial Functional Improvement in Patients With Major Depressive Disorder Through Nature-Based Tourism Activities
- An Individual-specific Synchrony Signature
- Antidepressant Response of DMT Masked With Propofol
- Aβ Dynamics in LLMD
- Basal Plasma Lithium Levels and Suicidal Events
- Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
- Biomarker-guided rTMS for Treatment Resistant Depression
- Brain Changes During Social Reward Psychotherapy for Mid- and Late-Life Suicidality
- CARED : A Novel Rapid Treatment Paradigm for Depression
- Causal Role of Delta-beta Coupling for Goal-directed Behavior in Anhedonic Depression
- Cerebral and Anti-inflammatory Response Through Exercise - Mechanisms In Depressive Disorders
- Chinese Longitudinal and Systematic Study of Bioplar Disorder
- Cohort Study on Medical Students' Mental Health
- Comorbid Obesity and Depression With an Anti-inflammatory Medication
- DBS for Depression
- DBS for TRD With the Medtronic Percept PC
- Decoding and Modulating Affective Brain States
- Deep TMS for Comorbid Depression and Cognitive Impairment in Older Adults
- Defining Neurobiological Links Between Substance Use and Mental Illness
- Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity
- E-field Guided iTBS for Treatment Resistant Depression
- Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder
- Effectiveness of an Integrated Care Pathway for Depression: Cluster Randomized Controlled Trial
- Efficacy of Statins Among Major Depressive Disorder
- Enhancing Veteran-Clinical Collaboration in VA PRRCs
- Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
- Evaluating tDCS Brain-stimulation in Depression Using MRI
- Evaluation of a Male-specific Psychotherapeutic Program for Major Depressive Disorders
- Evaluation of the Impact of the EDIT-B® Blood Test on the Health Status of Patients Presenting a Major Depressive Episode. Clinical Utility and Medico-Economic Aspects
- Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
- Exercise-priming of CBT for Depression: the CBT+ Trial
- Extended Effects of Cannabis Abstinence on Clinical Symptoms and Cognition in Depression
- Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD)
- Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
- Genetic Counselling in the Prevention of Mental Health Consequences of Cannabis Use
- Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
- Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness
- INflammation-based Stratification for Immune-Targeted Augmentation in Major Depressive Disorder
- Identifying Cerebral Hemodynamic Patterns in Mood Disorders and Mild Cognitive Impairment: A Functional Near-Infrared Spectroscopy (fNIRS) Study
- Identifying Local Field Potential Biomarkers for Treatment-Resistant Major Depression With Deep Brain Stimulation
- Imaging Depression in Parkinson's Disease
- Impact of Psychomotor Therapy on the Quality of Life in Depression
- In Vivo Cortical Excitability Modulation in Major Depressive Disorder
- In-patient SCC TMS
- Integrated Suicide & Trauma Therapy for Suicide Risk
- Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
- Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
- Invasive Decoding and Stimulation of Altered Reward Computations in Depression Patients
- Investigating the Neural Mechanisms of Repetitive Brain Stimulation With Invasive and Noninvasive Electrophysiology in Humans
- JAK Signaling in Depression
- Ketamine Augmentation of ECT in Treatment-Resistant Depression
- Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression
- Left vs. Right Non-Inferiority Trial
- Linking Affective Dynamics in Response to Daily Stress to Peripheral Vascular Function in Working Age Adults
- Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
- Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
- Magnesium Bisglycinate in Major Depressive Disorder
- Maintenance rTMS for Depression (Maitr-De)
- Maternal Mental Health Trial
- Measuring Psychomotor Response to L-DOPA Challenge As a Biomarker for Outcomes in Late-Life Depression: a Pilot Feasibility Trial
- Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
- Mechanisms of Rumination Change in Adolescent Depression
- Metabolic Profiling of Esketamine Treatment in Depressive Disorder
- MicroRNA Correlates of Childhood Maltreatment and Suicidality
- Mindful Self-Compassion for Anxiety Disorders and Depression
- Mindful Self-compassion for Anxiety and Depression: Impact of Delivery Method
- Mindfulness Engaged Neurostimulation for Depression (MEND II)
- Multimodal Clinical Study of Electroconvulsive Therapy and Magnetic Seizure Therapy
- NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder
- NMDA Modulation in Major Depressive Disorder
- Natural History of Depression, Bipolar Disorder and Suicide Risk
- Near Infrared Spectroscopy (NIRS) for Assessment of Depression
- Neural Circuit Effects of Ketamine in Depression
- Neural Correlates of Stress and Perceived Control in Adolescent Depression
- Neural Response to Inflammatory Challenge in Major Depressive Disorder
- Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
- Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV
Related conditions
Trials recruiting for Major depressive disorder often also study these conditions. Each links to its own recruiting-trial list.
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Major depressive disorder trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.